Search Results for Merck (Corporate Dealmaker)

Advanced Search

Sort ByDate Relevance	Search InCorporate Dealmaker The entire Deal Blogs Network

12 result(s) displayed (1 - 12 of 12):

Merck-Schering Day One (from Corporate Dealmaker)

Merck & Co. (NYSE:MRK) closed its $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP). The deal makes Merck the world's No. 2 drugmaker behind industry juggernaut Pfizer Inc. (NYSE:PFE), which had its own Day One on Oct. 16 after its $68 billion acquisition of Wyeth. Now that Merck and Schering-Plough...

Posted on November 4, 2009 5:04 PM

What a merged Merck-Schering will look like (from Corporate Dealmaker)

After it closes the $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP), Merck & Co. (NYSE:MRK) will reorganize into five main units, with animal health and consumer healthcare operating as separate business units. The other divisions are global human health, manufacturing and Merck Research Laboratories. The company also will create new...

Posted on August 31, 2009 2:41 PM

More musings on pharma megamergers (from Corporate Dealmaker)

Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid for Schering Plough Corp. (NYSE:SGP) sparked fresh speculation on whether pharma megamergers create value and whether industry consolidation would continue. We've done our share of analysis. Recently, Baz Hiralal posted this solid roundup...

Posted on June 2, 2009 2:46 PM

A case for pharma, toothpaste and toilet paper (from Corporate Dealmaker)

Does a business model combining pharmaceutical drugs and consumer products make for good corporate strategy? It's a question nearly every pharma giant has considered at one point or another. Well, the findings of a new study from pharmacy benefits management provider Medco Health Solutions adds another data point to the...

Posted on May 13, 2009 1:34 PM

Sanofi-Aventis takes axe to pipeline, M&A persists (from Corporate Dealmaker)

After about five months on the job, Sanofi-Aventis SA (NYSE:SNY) chief executive Chris Viehbacher is making his presence felt as the company reports profits are up about 16% and confirmed 2009 guidance.Viehbacher, on the hunt for acquisitions, cut 14 drugs in development from its pipeline of 65 -- including four...

Posted on April 29, 2009 2:53 PM

Three more pharma megamergers to go? (from Corporate Dealmaker)

London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...

Posted on April 23, 2009 9:14 AM

Merck Serono launches corporate venture fund (from Corporate Dealmaker)

It's been a long time since we've seen a corporate venture capital fund launched, what with companies laser focused on their core businesses and balance sheets. So we took notice when Merck Serono, a division of Merck KGaA, launched a $54.7 million fund to invest in biotechnology startups. Merck Serono...

Posted on March 23, 2009 3:54 PM

Pharma strategists discovered by WSJ (from Corporate Dealmaker)

An article in Monday morning's Wall Street Journal notes: "As the drug industry wrestles with major challenges, some top companies are turning to a new kind of executive for help: strategy master." Well, sort of. It's true that Big Pharma's well publicized troubles have resulted in some high-profile hires at...

Posted on April 14, 2008 3:56 PM

Pharma CFOs should be more strategic, survey says (from Corporate Dealmaker)

Ernst & Young has released a survey of 95 drug industry executives that shows heightened expectations for chief financial officers. As the industry grapples with slowing sales, tightening regulations, more aggressive generic competition, rapid globalization and a mountain of expiring patents, CFOs are expected to look beyond bean-counting and become...

Posted on March 28, 2008 9:01 AM

Nothing generic about returns on Hospira's Mayne Pharma deal (from Corporate Dealmaker)

Hospira Inc. CEO Christopher Begley said in a statement in September 2006 that the $2.1 billion purchase of Australian generic cancer drugs group Mayne Pharma Ltd. would add to Hospira's earnings per share in 2007. Lo and behold, the company just reported a 60% jump in fourth-quarter net income. No...

Posted on February 29, 2008 12:17 PM

For pharma, a nongeneric problem in corporate development (from Corporate Dealmaker)

All corporate dealmakers face challenges that are more or less unique to their industries. But it's hard to think of a set of corp dev choices as industry-specific--and as stark--as those in the pharma world. Yesterday the patent for Fosomax...

Posted on February 7, 2008 9:05 AM

Are method patents still valuable? (from Corporate Dealmaker)

Intellectual property issues are looming larger for most companies, but nowhere do they matter more than in the biotechnology industry. That is why a couple of recent decisions on so-called method patents in biotech have attracted such wide interest - and raised so many questions. The first case involved...

Posted on February 15, 2005 1:43 PM